<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461797</url>
  </required_header>
  <id_info>
    <org_study_id>biopsystudy</org_study_id>
    <nct_id>NCT02461797</nct_id>
  </id_info>
  <brief_title>Evaluation of Nasal Mucosal Permeability in Controls and House Dust Mite Allergic Rhinitis Patients</brief_title>
  <official_title>Evaluation of Nasal Mucosal Permeability in Controls and House Dust Mite Allergic Rhinitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, a critical role in the development of allergic rhinitis (AR) has been attributed to&#xD;
      the nasal epithelium. The airway epithelium forms a physical barrier, protecting the nasal&#xD;
      mucosa and underlying organs from damage from contact with exogenous particles. The nasal&#xD;
      epithelial barrier is primarily determined by the integrity of the airway epithelium, in&#xD;
      which epithelial cells are connected to each other by complex network structures like tight&#xD;
      junctions (TJs), ultimately sealing off the paracellular space. TJs consist of different&#xD;
      transmembrane proteins including occludin, tricellulin, the claudin family, and junctional&#xD;
      adhesion molecules. TJ form intercellular homodimers/heterodimers between neighboring cells.&#xD;
      Scaffold adaptor proteins like cingulin and the zonula occludens family connect the&#xD;
      transmembrane proteins to the actin cytoskeleton.&#xD;
&#xD;
      Disturbed TJ function can facilitate the entrance of foreign pathogens and antigens into the&#xD;
      submucosal layer, giving raise to allergic sensitization via increased access of allergens to&#xD;
      the dendritic cells and/or inducing persistent inflammation via activation of mast cells and&#xD;
      other inflammatory cells residing in the upper airways. Chronic disorders like allergic&#xD;
      asthma, inflammatory bowel disease and atopic dermatitis have been linked to defective or&#xD;
      altered TJ function. Recently, an impaired epithelial barrier function was found in patients&#xD;
      with chronic rhinosinusitis with nasal polyps (CRSwNP), suggesting changes in TJ arrangement&#xD;
      in the nasal cavity. CRSwNP presents a similar inflammation of the sinonasal cavities as&#xD;
      found in AR patients, i.e. a Th2 cytokine driven inflammation with tissue eosinophilia.&#xD;
      Nevertheless, the role of TJs and its regulation has not been investigated in AR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in Transepithelial electrical resistance (TEER)</measure>
    <time_frame>every 30 min over 2 hours</time_frame>
    <description>Nasal biopsies will be mounted in modified 3 ml Ussing chambers. Experiments will be performed in open-circuit conditions. Transepithelial electrical resistance (TEER) will be calculated from the voltage deflections induced by bipolar constant-current pulses of 16 mA every 60 s with duration of 200 ms and will be recorded every 30 min over 2 h. The average of all time points of the 2 biopsy samples/patient will be used and will be presented as Ωxcm².</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in mucosal permeability</measure>
    <time_frame>every 30 min over 2 h</time_frame>
    <description>The paracellular probe, fluorescently labelled dextran 4 kDa (FD4) (2 mg/ml) will be used to determine the mucosal permeability. FD4 will be added to the mucosal compartment and serosal samples will be collected every 30 min over 2 h. The fluorescence level will be measured using a fluorescence reader. The average of time points 60, 90 and 120 min of the 2 biopsy samples/patient will be used to express mucosal permeability.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>biopsy of nasal mucosa healthy controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR patients with use of nasal corticoid spray</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>biopsy of nasal mucosa allergic rhinitis to house dust mite with nasal corticosteroid spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR patients without medication</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>biopsy of nasal mucosa allergic rhinitis to house dust mite without any use of medication for symptom control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>healthy controls</intervention_name>
    <description>biopsy of nasal mucosa for healthy controls</description>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AR patients without medication</intervention_name>
    <description>biopsy of nasal mucosa for allergic rhinitis patients without allergy medication</description>
    <arm_group_label>AR patients without medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AR patients with use of nasal corticoid spray</intervention_name>
    <description>biopsy of nasal mucosa for allergic rhinitis patients with use of nasal corticoid spray</description>
    <arm_group_label>AR patients with use of nasal corticoid spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with an ARIA-based diagnosis of persistent moderate/severe AR (≥ 2 nasal&#xD;
             symptoms suggestive of allergic rhinitis and positive skin prick tests to HDM (HAL&#xD;
             Allergy, Leiden, The Netherlands), and with VAS score for total nasal symptoms of more&#xD;
             than 5&#xD;
&#xD;
          2. Age &gt; 18 and &lt; 60 years.&#xD;
&#xD;
          3. Possibility to give reliable information and written informed consent&#xD;
&#xD;
          4. For AR group with nasal corticosteroid spray: Patients that use nasal corticosteroid&#xD;
             spray for at least three weeks prior to the study, with a minimum application of two&#xD;
             puffs per nostril once a day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No common cold in the last 4 weeks&#xD;
&#xD;
          2. Patients on prolonged use of decongestive nose sprays, suffering from so-called&#xD;
             rhinitis medicamentosa&#xD;
&#xD;
          3. A. For healthy controls and AR without use of nasal spray: Patients using other nasal&#xD;
             or oral medication affecting nasal function, like nasal corticosteroids,&#xD;
             anticholinergics, cromoglycates, leukotriene antagonists, ACE inhibitors less than 4&#xD;
             weeks before start of the study.&#xD;
&#xD;
             B. For AR group with use of nasal corticosteroid spray: Patients using other nasal or&#xD;
             oral medication affecting nasal function, like anticholinergics, cromoglycates,&#xD;
             leukotriene antagonists, ACE inhibitors less than 4 weeks before start of the study.&#xD;
&#xD;
          4. Nasal endoscopic evidence of rhinosinusitis w/wo NP or structural abnormalities such&#xD;
             as clinically relevant septal deviation (septum reaching concha inferior or lateral&#xD;
             nasal wall) or septal perforation&#xD;
&#xD;
          5. Patients on immunotherapy (IT) for house dust mite (HDM) or with history of IT for HDM&#xD;
&#xD;
          6. Patient with a psychiatric, addictive, or any disorder of which the investigators feel&#xD;
             that this may compromise the ability to give truly informed consent for participation&#xD;
             in this study or provide reliable information on the questionnaire&#xD;
&#xD;
          7. Patients being enrolled in other clinical trials&#xD;
&#xD;
          8. Pregnancy or breastfeeding&#xD;
&#xD;
          9. Malignancies or severe comorbidity&#xD;
&#xD;
         10. Contra-indication for local anesthesia with cocaine 5%&#xD;
&#xD;
         11. Smoking&#xD;
&#xD;
         12. Use of anticoagulation medication&#xD;
&#xD;
        Healthy controls will meet the same exclusion criteria, with additional inclusion criteria:&#xD;
&#xD;
          1. Absence of nasal symptoms&#xD;
&#xD;
          2. Negative history of respiratory allergy&#xD;
&#xD;
          3. Negative skin prick test (SPT) results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hellings, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ORL</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

